Please login to the form below
trastuzumab emtansine
This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.
Roche preps new Kadcyla filings after phase 3 trial win
In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,
Latest news
-
Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3
The Japanese drugmaker’s has started recruiting patients into two pivotal trials of its ADC trastuzumab deruxtecan (DS-8201), one of which will pit the drug against Kadcyla (ado-trastuzumab emtansine) ... in HER2 positive, unresectable and/or
-
AZ nabs US approval for new leukaemia drug Lumoxiti
Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
-
NICE relents on Kadcyla after Roche pricing negotiations
The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that
-
A new decade of disruption: meeting the biosimilar challgenge
High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab). ... An example can be seen in Roche’s introduction
-
Roche in "unprecedented" launch period for new medicines
The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to
More from news
Approximately 5 fully matching, plus 52 partially matching documents found.
Latest Intelligence
-
An eye towards the biobetter in South Korea
It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Senior Medical Writer
-
Competitive Salary
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
- Account Manager- Healthcare Advertising
-
Negotiable
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Medical Writers
-
Competitive Salary and Benefits
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
-
Account Director
-
Excellent benefits
-
New Business Director - PR
-
Competitive Salary and benefits
Subscribe to our email news alerts
- Heart Lung Machine Market to See 6.9% CAGR Growth to 2025: Growth Factor & Trends
- Ultrasonic Dental Unit Market Trends Shows a Steady 0.3% CAGR Growth to 2023: Market Study Report
- Prefilled Syringe Market Set to Register 9.0% CAGR to 2023: Market Study Report
- Carbide Tipped Needle Holders Market to Grow at a 14.5 % CAGR to 2023
- Keyhole Limpet Hemocyanin (KLH) Market Set to Register 1.2% CAGR to 2023: Market Study Report
- Medical Refrigerator Market Set to Register 2.4% CAGR to 2023
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
